Literature DB >> 15613357

Productive replication of human adenovirus type 5 in canine cells.

Vladimir V Ternovoi1, Long P Le, Natalya Belousova, Bruce F Smith, Gene P Siegal, David T Curiel.   

Abstract

Development of immunocompetent patient-like models that allow direct analysis of human adenovirus-based conditionally replicative adenoviruses (CRAds) would be beneficial for the advancement of these oncolytic agents. To this end, we explored the possibility of cross-species replication of human adenovirus type 5 (Ad5) in canine cells. With a panel of canine tumor cell lines of both epithelial and mesenchymal derivations, we demonstrate that human Ad5 can productively infect canine cells. Since the biological behavior and clinical presentation of certain dog tumors closely resemble those of their human counterparts, our results raise the possibility of exploiting canine models for preclinical analysis of candidate CRAd agents designed for human virotherapy.

Entities:  

Mesh:

Year:  2005        PMID: 15613357      PMCID: PMC538546          DOI: 10.1128/JVI.79.2.1308-1311.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

Authors:  J Nemunaitis; F Khuri; I Ganly; J Arseneau; M Posner; E Vokes; J Kuhn; T McCarty; S Landers; A Blackburn; L Romel; B Randlev; S Kaye; D Kirn
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

Review 2.  Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

Authors:  D Kirn
Journal:  Gene Ther       Date:  2001-01       Impact factor: 5.250

3.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.

Authors:  J Nemunaitis; C Cunningham; A Buchanan; A Blackburn; G Edelman; P Maples; G Netto; A Tong; B Randlev; S Olson; D Kirn
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

Review 4.  Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.

Authors:  D Kirn
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

Review 5.  Replicative adenoviruses for cancer therapy.

Authors:  R Alemany; C Balagué; D T Curiel
Journal:  Nat Biotechnol       Date:  2000-07       Impact factor: 54.908

6.  Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer.

Authors:  Erin B Dickerson; Susan Fosmire; Marcia L Padilla; Jaime F Modiano; Stuart C Helfand
Journal:  J Immunother       Date:  2002 Jan-Feb       Impact factor: 4.456

7.  A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.

Authors:  Akseli Hemminki; Anna Kanerva; Eric J Kremer; Gerd J Bauerschmitz; Bruce F Smith; Bin Liu; Minghui Wang; Renee A Desmond; Anne Keriel; Brian Barnett; Henry J Baker; Gene P Siegal; David T Curiel
Journal:  Mol Ther       Date:  2003-02       Impact factor: 11.454

8.  Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.

Authors:  P A Vasey; L N Shulman; S Campos; J Davis; M Gore; S Johnston; D H Kirn; V O'Neill; N Siddiqui; M V Seiden; S B Kaye
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

9.  Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.

Authors:  Della Makower; Alla Rozenblit; Howard Kaufman; Morris Edelman; Maureen E Lane; James Zwiebel; Hilda Haynes; Scott Wadler
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

10.  An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Authors:  J R Bischoff; D H Kirn; A Williams; C Heise; S Horn; M Muna; L Ng; J A Nye; A Sampson-Johannes; A Fattaey; F McCormick
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

View more
  19 in total

1.  A novel method of boron delivery using sodium iodide symporter for boron neutron capture therapy.

Authors:  Sanath Kumar; Svend O Freytag; Kenneth N Barton; Jay Burmeister; Michael C Joiner; Bijan Sedghi; Benjamin Movsas; Peter J Binns; Jae Ho Kim; Stephen L Brown
Journal:  J Radiat Res       Date:  2010       Impact factor: 2.724

Review 2.  Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism.

Authors:  J Michael Mathis; Phoebe L Stewart; Zheng B Zhu; David T Curiel
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

3.  A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.

Authors:  Eduardo Laborda; Cristina Puig-Saus; Alba Rodriguez-García; Rafael Moreno; Manel Cascalló; Josep Pastor; Ramon Alemany
Journal:  Mol Ther       Date:  2014-01-22       Impact factor: 11.454

Review 4.  Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Authors:  M A Witlox; M L Lamfers; P I J M Wuisman; D T Curiel; G P Siegal
Journal:  Bone       Date:  2006-12-26       Impact factor: 4.398

5.  Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy.

Authors:  Ivaylo Gentschev; Sandeep S Patil; Marion Adelfinger; Stephanie Weibel; Ulrike Geissinger; Alexa Frentzen; Nanhai G Chen; Yong A Yu; Qian Zhang; Gregory Ogilvie; Aladar A Szalay
Journal:  Bioengineered       Date:  2012-10-23       Impact factor: 3.269

6.  Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus.

Authors:  Jason C Steel; Brian J Morrison; Poonam Mannan; Mones S Abu-Asab; Oliver Wildner; Brian K Miles; Kevin C Yim; Vijay Ramanan; Gregory A Prince; John C Morris
Journal:  Virology       Date:  2007-08-28       Impact factor: 3.616

7.  Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model.

Authors:  Karoly Toth; Jacqueline F Spencer; Debanjan Dhar; John E Sagartz; R Mark L Buller; George R Painter; William S M Wold
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

8.  In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection.

Authors:  Hideyo Ugai; Minghui Wang; Long P Le; David A Matthews; Masato Yamamoto; David T Curiel
Journal:  J Mol Biol       Date:  2009-10-21       Impact factor: 5.469

9.  In situ adenovirus vaccination engages T effector cells against cancer.

Authors:  Sebastian Tuve; Ying Liu; Khajornsak Tragoolpua; Jeffrey Daniel Jacobs; Roma Christine Yumul; Zong-Yi Li; Robert Strauss; Karl-Erik Hellström; Mary Lenora Disis; Steve Roffler; André Lieber
Journal:  Vaccine       Date:  2009-04-16       Impact factor: 3.641

10.  New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.

Authors:  J F Spencer; J E Sagartz; W S M Wold; K Toth
Journal:  Cancer Gene Ther       Date:  2009-05-29       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.